Posted by Michael Wonder on 19 Nov 2022
COVID-19 vaccine safety report (17 November 2022)
17 November 2022 - To 13 November 2022, the TGA has received 706 reports which have been assessed as likely to be myocarditis from about 44.3 million doses of Comirnaty (Pfizer) and 116 reports which have been assessed as likely to be myocarditis from about 5.4 million doses of Spikevax (Moderna).
To 13 November 2022, we have received about 4,290 reports from approximately 3.7 million doses of Comirnaty (Pfizer) and Spikevax (Moderna) in 12-17 year olds. The most commonly reported reactions are chest pain, headache, dizziness, nausea and fever.
